Safety Profile of the Non-steroidal Anti-inflammatory Drug Celecoxib in the Short-Term Management of Acute Non-cancer Pain: A Systematic Review with Meta-analysis of Randomised Controlled Trials.
Carlos Mesa-Castrillon, Ye Tian, Jessica Hughes et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the safety of celecoxib for short-term management of acute non-cancer pain in 10,693 participants across 50 studies. The analysis found no significant difference in severe adverse events between celecoxib and placebo (RR 0.44) or NSAIDs (RR 0.89), but celecoxib had a lower risk of gastrointestinal events compared to opioids (RR 0.34).
Key findings
- Celecoxib showed no significant difference in severe adverse events compared to placebo (RR 0.44).
- No difference in gastrointestinal adverse events between celecoxib and NSAIDs (RR 0.89).
- Celecoxib had a lower risk of gastrointestinal events compared to opioids (RR 0.34).
- Celecoxib reduced nausea risk compared to placebo (RR 0.75) and non-selective NSAIDs (RR 0.80).
Why it matters
Understanding the safety profile of celecoxib in acute non-cancer pain management is crucial for clinicians to make informed decisions about pain relief options, especially in patients at risk for gastrointestinal complications.
What to keep in mind
Most studies included had some risk of bias concerns, and the overall certainty of evidence for most outcomes was very low.